Michel C. Nuckols
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michel C. Nuckols has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- B. Frank Gupton
Virginia Commonwealth University
2 shared publications - Adam E. S. Gymer
Pfizer (United Kingdom)
1 shared publication - Chanaka M. Amarasekarage
TCG GreenChem
1 shared publication - Charles S. Shanahan
Medicines For All Institute
1 shared publication - Chiranjeevi Barreddi
Virginia Commonwealth University
1 shared publication - Chris H. Senanayake
TCG GreenChem, Inc. , 701 Charles Ewing Blvd
1 shared publication
Latest Publications
- Open Access
- 24 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
High Yielding, Multigram-Scale Synthesis of TBAJ-876 Fragment, 876A-B
TBAJ-876 is an anti-tuberculosis drug shown to have high activity against multi-drug resistant tuberculosis (TB). We report a very efficient synthesis of the TBAJ-876 fragment 876A-B using an aldol condensation strategy starting from 6-bromo-3,4-dihydroquinolin-2(H)-one. The synthesis has been accomplished at multigram scale without the need of chromatography purification steps.
- 24 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessHigh Yielding, Multigram-Scale Synthesis of TBAJ-876 Fragment, 876A-B
TBAJ-876 is an anti-tuberculosis drug shown to have high activity against multi-drug resistant tuberculosis (TB). We report a very efficient synthesis of the TBAJ-876 fragment 876A-B using an aldol condensation strategy starting from 6-bromo-3,4-dihydroquinolin-2(H)-one. The synthesis has been accomplished at multigram scale without the need of chromatography purification steps.
- Open Access
- 30 January 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Development of New Catalytic Asymmetric Routes towards a Cost-Driving Building Block of Nirmatrelvir
Nirmatrelvir is an inhibitor of SARS-CoV-2 main protease and is the active ingredient in PaxlovidTM. Nirmatrelvir presents a significant synthetic challenge, in no small part due to a cost-driving lactam containing fragment with two stereogenic centers. Our goal was to help decrease the cost of nirmatrelvir, by developing a scalable low-cost synthesis of this fragment, avoiding use of cryogenic conditions reported in the initial route. Herein we disclose three catalytic asymmetric routes to-wards this fragment, via i) chiral Lewis acid (copper) catalysis, ii) chiral Brønsted base organocatalysis and iii) chiral bifunctional hydrogen-bond-donor organocatalysis.
- 30 January 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of New Catalytic Asymmetric Routes towards a Cost-Driving Building Block of Nirmatrelvir
Nirmatrelvir is an inhibitor of SARS-CoV-2 main protease and is the active ingredient in PaxlovidTM. Nirmatrelvir presents a significant synthetic challenge, in no small part due to a cost-driving lactam containing fragment with two stereogenic centers. Our goal was to help decrease the cost of nirmatrelvir, by developing a scalable low-cost synthesis of this fragment, avoiding use of cryogenic conditions reported in the initial route. Herein we disclose three catalytic asymmetric routes to-wards this fragment, via i) chiral Lewis acid (copper) catalysis, ii) chiral Brønsted base organocatalysis and iii) chiral bifunctional hydrogen-bond-donor organocatalysis.